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ABSTRACT 
 A new series of 4-methyl-quinolines was synthesized as potential cruzain inhibitors using 
Doebner-Von Miller synthesis. The compounds (1a-f) are undergoing analysis in order to 
guarantee their purities and further explore their biological activity. 
Keywords: Quinoline, Doebner-Von Miller, Cruzain, Trypanosoma cruzi, Chagas disease.  
1. Introduction 
Quinolines play an important role towards the development and application of new 
pharmaceutical agents. Due to their remarkable biological activities, quinolines have been launched 
as antimalarial, antiviral, antibacterial, antifungal, antiprotozoal, anthelmintic, anesthetic, 
antiasthmatic, anticancer, and cardiotonic drugs¹. Quinoline moiety containing compounds have 
lead this class of molecule to a list of top five most common six-membered aromatic nitrogen 
heterocycles approved by FDA ²; as well as substituted quinolines have been proved to be ubiquitous 
motifs in a variety class of molecules regarding drug discovery³. 
Chagas disease, or American trypanosomiasis, is listed as one of the 17 neglected diseases 
appointed by WHO, affecting approximately 10 million people in Latin America, as well as the 
leading cause of cardiomyopathy4. The infection is causes by Trypanosoma cruzi, a flagellate parasite 
transmitted after triatomine bug. The clinical arsenal used against it is restricted to  the two available 
drugs: benzonidazole and nifurtimox. Both treatments face a significant problem5 because of toxic 
effects after long exposure time, as well as the need for high doses due to the emergence of drug 
resistance6. 
Quinolines have been synthesized and had their biological activity evaluated regarding 
Chagas disease. Tryciclic quinolines obtained via a multicomponent reaction proved to be active 
against Trypanosoma cruzi by non-specific metabolic pathway.7 It is believed that hybrids containing 
quinolinic pharmacophore are able to form iron complexes resulting in deprivation of the 
fundamental nutrient for cell growth and division8. Among the potential targets for the 
development of new anti-T. cruzi drugs, such as lanosterol 14 α-demethyalse9, tryphanothione 
reductase10; there is another unique enzyme to be further explored which is the major cysteine 
protease cruzain, a fundamental enzyme for the development of the parasite life cycle within the 
 host cell11-12. Few years back, a new class of non-peptidic inhibitors of cruzain was reported, the 
molecules obtained through substrate-activity screening alongside x-ray structure had shown the 
pivotal role of quinoline moiety on the discovery of promising inhibitors. 13 
Several traditional and modified approaches have been described towards the synthesis of 
quinolines¹. Combes, Conrad-Limpach and Skraup synthesis are examples of them. In 1881, Doebner 
and Von Miller proposed an alternative method to the Skraup protocol. They replaced the glycerol 
with an α,β-unsaturated ketone, but keeping the aniline in the reaction medium. This protocol offers 
the usage of a variety of catalysts such as Lewis and Brönsted acids, moreover, microwave 
irradiation can be applied in order to synthesize them. 
Herein, we report the synthesis of novel substituted quinolines as promising cruzain 
inhibitors aiming the anti-T. cruzi activity through Doëbner-Von Miller reaction employing six 
substitute anilines, and methyl vinyl ketone assisted by ρ-toluenesulfonic acid as Brönsted acid. 
2. Results and discussion 
The synthetic route adopted for the preparation of target compounds 1a-f was outlined in 
scheme 1. The starting anilines were stirred for over a day up the boiling point of the solvent used 
to afford the quinolines. 
 
Not all compounds were able to be isolated and have their structures fully elucidated due to 
lack of available time and facilities during the chronogram initially planned. The compound 1a, 
however, underwent a purification and NMR analysis, and hence served as standard for the other 
reactions. It is important to highlight the fact that the compounds 1b-d were identificated after a 
crude NMR analysis were performed, showing their unique proton signals, but some compounds 
were not purified neither had their NMR spectra obtained. Moreover, the compounds 1e-f, were 
purified by column chromatography, and were not elucidated by NMR methods as well; however it 
was assumed that those compounds were afforded after TLC plates were run. The only available 
method to follow up the synthetic approach was though TLC obtained after column 
chromatography, compared with 1a’s TLC fashion, as mentioned before. The ¹H NMR and IR spectra 
are available at Supplementary data section. 
The ¹H NMR spectrum of 1a shows a low-field signal at 8.77 ppm, and coupling constant of 
approximately 4 Hz, typical of the 2-position hydrogen. This signal also can be observed at the crude 
samples, indicating that desired molecule was synthesized*¹.  
The evaluation of biological activity is underway, and these molecules are part of preliminary 
analysis of structure activity-relationship between quinolines and cruzaine according to unpublished 
 data based on computational screening. The synthetic route elected in order to afford them 
provides a methyl group in position 4, which allows the quinoline core to be further functionalized. 
The methyl group positioned at the fourth carbon allows for a possible increase in 
complexity; for example it can potentially be oxidized from the alcohol up to the carboxylic acid. The 
presence of these functional groups gives the opportunity for optimization of the interactions 
between the target. This aim can be reached by adding a linkage chain, allowing the molecule to 
have another pharmacophore group position in order to increase drug-enzyme interaction.*² 
 
3. Conclusion 
We reported herein a synthesis of a series of quinoline derivatives. This work is in its early 
stages, and is fundamental to conclude the chemical part in order to move forward for the biological 
part, and eventually summarize a structure-activity relationship and further explore the cruzain’s 
role in Chagas disease and drug candidates.  
 
4. Experimental section 
 
1H NMR spectrum was recorded on Agilent 500 MHz spectrometer. Chemical shifts are reported in δ ppm values and were internally referenced to TMS (δ 0.00) for CDCl3. Infrared (FT-IR) spectra were recorded on Perkin Elmer Spectrum BX instrument for thin film (in acetone) or neat samples. All reactions were carried out with commercially available reagents and solvents and were used without any further purification.   4.1 General procedure for the synthesis of 1a-f 
The substituted anilines (0,1 g), methyl vinyl ketone (2.5 mol/eq.), and ρ-toluenesulfonic acid 
(1 mol/eq.) were added to a schlenk tube in 5 mL of 1,2-dichloroethane and stirred for 48 h in oil 
bath at approximately 85 °C. Then the reaction was quenched with saturated NaHCO3 solution and extracted with CH2Cl2 (20 mL x 2). The combined organic extracts were dried with Na2SO4, filtered, and evaporated under reduced pressure, the dark crude was purified by column chromatography 
on silica gel (mobile phase: dichloromethane:diethyl ether, 95:5) 
4.1.1. 1a 
Yellow powder. FT-IR (cm-1): 2925, 1594, 1493, 824.  ¹H NMR (500 MHzm CDCl3): δ 8.77 (d, J=4.2 Hz, 1 H, H2), 8.14 (d, J=2.1 Hz, 1 H, H5), 7.97 (d, J=9, 1 H, H8), 7.77 (dd, J=9.0, 2.1, 1 H, H7), 
7.25 (d, J=4.2 Hz, 1 H, H3), 2.67 (s, 3H, CH3). 
4.1.2. 1b 
Undergoing analysis 
4.1.3. 1c 
Undergoing analysis 
4.1.4. 1d 
 Undergoing analysis 
4.1.5. 1e 
Undergoing analysis 
4.1.6. 1f 
Undergoing analysis 
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of a manuscript. Small-molecule crystal structures are to be deposited with the Cambridge
Crystallographic Data Centre (http://www.ccdc.cam.ac.uk) and macromolecular structures with the
Protein Data Bank (http://www.rcsb.org). Full details on deposition procedures are available directly
from these data bases.
Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text
should be in single-column format. Keep the layout of the text as simple as possible. Most formatting
codes will be removed and replaced on processing the article. In particular, do not use the word
processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts,
superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each
individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns.
The electronic text should be prepared in a way very similar to that of conventional manuscripts (see
also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics
will be required whether or not you embed your figures in the text. See also the section on Electronic
artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your word processor.
Figures, schemes and tables
Please note that all figures, schemes and tables should be embedded in the relevant positions within
the manuscript file for ease of reference by the Editor and reviewers. Figures, schemes and tables
may also be supplied as separate source files, but must always be included within the manuscript
file as well.
Templates
Templates are provided to allow authors to view their paper in a style close to the final printed
form. Their use is optional. All manuscripts will be fully typeset from the author's electronic files. It
should be noted that due to defined typesetting standards and the complex requirements of electronic
publishing, the publisher will not always be able to exactly match the layout the author has submitted.
In particular, in the finished journal article, figures and tables are usually placed at the top or bottom
of pages. The template is only intended to be used in assisting with the preparation and submission
of manuscripts.
It should be noted that use of the journal templates is not a requirement and their adoption will neither
speed nor delay publication. Elsevier can handle most major word processing packages and in general
most formatting applied by authors for style and layout is replaced when the article is being typeset.
These templates contain a large number of macros. To ensure successful PDF conversion during online
submission, it is important that the author save a new document based on the template, rather than
saving the template itself. To use the template, the author should save the final document as a Word
file with a '.doc' extension (rather than the '.dot' extension).
The templates can be found at http://www.elsevier.com/bmc-templates.
Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered
1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this
numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be
given a brief heading. Each heading should appear on its own separate line.
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Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results.
Material and methods
Provide sufficient detail to allow the work to be reproduced. Methods already published should be
indicated by a reference: only relevant modifications should be described.
Theory/calculation
A Theory section should extend, not repeat, the background to the article already dealt with in the
Introduction and lay the foundation for further work. In contrast, a Calculation section represents a
practical development from a theoretical basis.
Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results
and Discussion section is often appropriate. Avoid extensive citations and discussion of published
literature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand
alone or form a subsection of a Discussion or Results and Discussion section.
Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in
appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix,
Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.
Vitae
When submitting a review article, authors should include biographical information for each author
as well as a black-and-white photograph. Each biography should be one paragraph (approximately
150-200 words) and should include date and place of birth, universities attended, degrees obtained,
principal professional posts held, present title, a line or two about the major research interests, and
anything else professionally relevant that is of special interest.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s)
of each author and check that all names are accurately spelled. Present the authors' affiliation
addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-
case superscript letter immediately after the author's name and in front of the appropriate address.
Provide the full postal address of each affiliation, including the country name and, if available, the
e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing
and publication, also post-publication. Ensure that the e-mail address is given and that contact
details are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as
a footnote to that author's name. The address at which the author actually did the work must be
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the
research, the principal results and major conclusions. An abstract is often presented separately from
the article, so it must be able to stand alone. For this reason, References should be avoided, but if
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should
be avoided, but if essential they must be defined at their first mention in the abstract itself.
Graphical abstract
A Graphical abstract is mandatory for this journal. It should summarize the contents of the article in
a concise, pictorial form designed to capture the attention of a wide readership online. Authors must
provide images that clearly represent the work described in the article. Graphical abstracts should be
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submitted as a separate file in the online submission system. Image size: please provide an image
with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable
at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF
or MS Office files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best
presentation of their images also in accordance with all technical requirements: Illustration Service.
Highlights
Highlights are a short collection of bullet points that convey the core findings of the article. Highlights
are optional and should be submitted in a separate editable file in the online submission system.
Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters,
including spaces, per bullet point). You can view example Highlights on our information site.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those
individuals who provided help during the research (e.g., providing language help, writing assistance
or proof reading the article, etc.).
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy];
the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes
of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of grants and awards. When
funding is from a block grant or other resources available to a university, college, or other research
institution, submit the name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or
not-for-profit sectors.
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word
processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate
the position of footnotes in the text and list the footnotes themselves separately at the end of the
article. Do not include footnotes in the Reference list.
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or
use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then
please supply 'as is' in the native document format.
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Regardless of the application used other than Microsoft Office, when your electronic artwork is
finalized, please 'Save as' or convert the images to one of the following formats (note the resolution
requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of
500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a
low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. Further information on the preparation of
electronic artwork.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A
caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep
text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in
the text) to other articles in the same Special Issue.
Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors
can be referred to, but the reference number(s) must always be given.
Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'
List: Number the references (numbers in square brackets) in the list in the order in which they appear
in the text.
Examples:
Reference to a journal publication:
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[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun.
163 (2010) 51–59.
Reference to a book:
[2] W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000.
Reference to a chapter in an edited book:
[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z.
Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2009, pp. 281–304.
Reference to a website:
[4] Cancer Research UK, Cancer statistics reports for the UK. http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/, 2003 (accessed 13.03.03).
In the text, references should be indicated by superscript Arabic numerals which run consecutively
through the paper and appear after any punctuation. Please ensure that all references are cited in
the text and vice versa. The reference list should preferably contain only literature references though
other information (e.g., experimental details) can be placed in this section. Preferably, each reference
should contain only one literature citation. Authors are expected to check the original source reference
for accuracy. Journal titles should be abbreviated according to American Chemical Society guidelines
(The ACS Style Guide; Dodd, J. S., Ed.; American Chemical Society: Washington, DC, 1997). A list of
currently accepted journal abbreviations may be found at http://elsevier.com/locate/bmcl. Formatting
for common references is shown below.
Scientific articles:
1. Barton, D. H. R.; Yadav-Bhatnagar, N.; Finet, J.-P.; Khamsi, J. Tetrahedron Lett. 1987, 28, 3111.
Books with editor:
2. Doe, J. S.; Smith, J. J. In Medicinal Chemistry; Roe, P., Small, J. K., Eds.; Pergamon: Oxford, 1990;
Vol. 1, pp 301 383.
Books without editor:
3. Doe, J. S.; Smith, J. J. Bioorganic Chemistry; Pergamon: Oxford, 1990, Chapter 6.
Theses:
4. Doe, J. S. Ph.D. Thesis, University of California at San Diego, January 2000.
Patent/Chem. Abstract:
5. Lyle, F. R. U.S. Patent 6,973,257, 1995; Chem. Abstr. 1995, 123, 2870.
Abstract of meeting papers:
6. Doe, J. S. Abstract of Papers, 195th National Meeting of the American Chemical Society, Anaheim,
CA; American Chemical Society: Washington, DC, 1995; Abstract 3028.
Material presented orally:
7. Doe, J. S. Presented at the 195th National Meeting of the American Chemical Society, Anaheim,
CA, March 1995; paper 205.
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.
Supplementary material
Supplementary material can support and enhance your scientific research. Supplementary files
offer the author additional possibilities to publish supporting applications, high-resolution images,
background datasets, sound clips and more. Please note that such items are published online exactly
as they are submitted; there is no typesetting involved (supplementary data supplied as an Excel
file or as a PowerPoint slide will appear as such online). Please submit the material together with the
article and supply a concise and descriptive caption for each file. If you wish to make any changes to
AUTHOR INFORMATION PACK 8 Jun 2016 www.elsevier.com/locate/bmc 12
supplementary data during any stage of the process, then please make sure to provide an updated
file, and do not annotate any corrections on a previous version. Please also make sure to switch off the
'Track Changes' option in any Microsoft Office files as these will appear in the published supplementary
file(s). For more detailed instructions please visit our artwork instruction pages.
Note that supplementary material is published online exactly as supplied (i.e. it is not typeset). The
typesetter is unable to implement corrections to supplementary material. Should any corrections be
necessary, authors should supply a revised supplementary material file.
RESEARCH DATA
Open data
This journal supports Open data, enabling authors to submit any raw (unprocessed) research data
with their article for open access publication under the CC BY license. More information.
Database linking
Elsevier encourages authors to connect articles with external databases, giving readers access to
relevant databases that help to build a better understanding of the described research. Please refer
to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR:
AT1G01020; CCDC: 734053; PDB: 1XFN). More information and a full list of supported databases.
CONTENT INNOVATION
AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article.
AudioSlides are brief, webinar-style presentations that are shown next to the online article on
ScienceDirect. This gives authors the opportunity to summarize their research in their own words
and to help readers understand what the paper is about. More information and examples are
available. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides
presentation after acceptance of their paper.
Chemical Compound Viewer (Reaxys)
You can enrich your article with visual representations, links and details for those chemical structures
that you define as the main chemical compounds described. Please follow the instructions to learn
how to do this.
3D molecular models
You can enrich your online articles by providing 3D molecular models (optional) in PDB, PSE or
MOL/MOL2 format, which will be visualized using the interactive viewer embedded within the article.
Using the viewer, it will be possible to zoom into the model, rotate and pan the model, and change
display settings. Submitted models will also be available for downloading from your online article
on ScienceDirect. Each molecular model will have to be uploaded to the online submission system
separately, via the '3D molecular models' submission category. More information.
Interactive plots
This journal enables you to show an Interactive Plot with your article by simply submitting a data
file. Full instructions.
Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal
for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded, and contain:
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the
Internet)
Printed version of figures (if applicable) in color or black-and-white
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• Indicate clearly whether or not color or black-and-white in print is required.
For any further information please visit our Support Center.
AFTER ACCEPTANCE
Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do
not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the
e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF
proofs which can be annotated; for this you will need to download the free Adobe Reader, version 9
(or higher). Instructions on how to annotate PDF files will accompany the proofs (also given online).
The exact system requirements are given at the Adobe site.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies
to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line
number. If, for any reason, this is not possible, then mark the corrections and any other comments
(including replies to the Query Form) on a printout of your proof and scan the pages and return via e-
mail. Please use this proof only for checking the typesetting, editing, completeness and correctness
of the text, tables and figures. Significant changes to the article as accepted for publication will only
be considered at this stage with permission from the Editor. We will do everything possible to get your
article published quickly and accurately. It is important to ensure that all corrections are sent back
to us in one communication: please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free
access to the final published version of the article on ScienceDirect. The Share Link can be used
for sharing the article via any communication channel, including email and social media. For an
extra charge, paper offprints can be ordered via the offprint order form which is sent once the
article is accepted for publication. Both corresponding and co-authors may order offprints at any
time via Elsevier's Webshop. Corresponding authors who have published their article open access do
not receive a Share Link as their final published version of the article is available open access on
ScienceDirect and can be shared through the article DOI link.
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Track your submitted article
Track your accepted article
You are also welcome to contact the Elsevier Contact Center.
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